EML4 and neoplasm: Additional evidence of the specificity of ponatinib’s antitumor activity was observed when ponatinib had minimal effects on an in vivo isogenic Ba/F3 tumor model dependent on oncogenic EML4-ALK (Supplementary Figure 1) in comparison with the approved ALK inhibitor crizotinib (200 mg/kg).